CTNM (Contineum Pharma) רווח נקי למניה (EPS TTM)

The confirmed price history on the EPS (TTM) chart demonstrates the impact of successes in developing anti-microglia agents and the progress of clinical tests for Contineum Therapeutics, Inc. (CTNM). The business relies on the creation of small molecules to combat pulmonary fibrosis and MS, targeting LPA1 receptors. The current figure is 21.50. The firm's priority remains global patent protection and the development of early-stage oral medications.
CTNM (Contineum Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net income per share over a rolling twelve-month period. By analyzing the history of YoY EPS (TTM) changes, an investor determines the rate of real business value growth relative to market quotes. This metric compares current results with the same period from the previous year, revealing the efficiency of capital management. For Contineum Therapeutics, Inc. (CTNM), this indicator reflects financial stability during the development of innovative drugs for nerve tissue regeneration.